These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21314250)

  • 1. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.
    Michallet M; Sobh M; Morisset S; Kraghel S; Nicolini FE; Thomas X; Bienvenu AL; Picot S; Nicolle MC; Vanhems P
    Med Mycol; 2011 Oct; 49(7):681-7. PubMed ID: 21314250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
    Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
    Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
    Desplanques PY; Burlacu R; Poinsignon V; Boussion H; Borget I; Wyplosz B; de Botton S; Billaud E; Chachaty E; Gachot B; Netzer F; Micol JB
    Med Mal Infect; 2014 Apr; 44(4):174-9. PubMed ID: 24656841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
    Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
    Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
    Myoken Y; Sugata T; Kyo T; Fujihara M; Mikami Y
    J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
    Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
    Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
    Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
    Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
    Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
    Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
    Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
    Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M
    Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center.
    Jain S; Kapoor G
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e1-5. PubMed ID: 24686246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
    Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
    Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of the incubation period of invasive aspergillosis by survival models in acute myeloid leukemia patients.
    Bénet T; Voirin N; Nicolle MC; Picot S; Michallet M; Vanhems P
    Med Mycol; 2013 Feb; 51(2):214-8. PubMed ID: 22662757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.